GoodRx Holdings (GDRX) Long-Term Deferred Tax (2019 - 2026)

GoodRx Holdings has disclosed Long-Term Deferred Tax across 7 years of filings, most recently posting $47.3 million for Q2 2026.

• In Q2 2026, Long-Term Deferred Tax fell 38.67% year-over-year to $47.3 million; the TTM figure through Jun 2026 stood at $47.3 million (down 38.67% YoY), while the FY2025 annual figure was $57.1 million, down 26.0% from the prior year.
• Long-Term Deferred Tax came in at $47.3 million for Q2 2026 at GoodRx Holdings, down from $53.0 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $77.2 million in Q4 2024 to a low of $47.3 million in Q2 2026.
• Average Long-Term Deferred Tax over 4 years is $64.6 million, with a median of $65.3 million recorded in 2023.
• Year-over-year, Long-Term Deferred Tax advanced 18.25% in 2024 and sank 38.67% in 2026.
• Over 4 years, Long-Term Deferred Tax stood at $65.3 million in 2023, then increased by 18.25% to $77.2 million in 2024, then fell by 26.0% to $57.1 million in 2025, then declined by 17.12% to $47.3 million in 2026.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $47.3 million in Q2 2026, $53.0 million in Q1 2026, and $57.1 million in Q4 2025.